Stephen Hahn makes first post-FDA move, join­ing board of un­der-the-radar Philadel­phia com­pa­ny

Phar­ma crit­ics ar­gue there is a re­volv­ing door be­tween the FDA and in­dus­try, as ca­reer staffers ro­tate be­tween the reg­u­la­to­ry body and the com­pa­nies they reg­u­late. On Tues­day, for­mer agency chief Stephen Hahn added an­oth­er ar­row to their quiv­ers.

Hahn has ac­cept­ed a board po­si­tion at Black­fynn, a lit­tle-known com­pa­ny in Philadel­phia with sev­er­al for­mer re­searchers from the Uni­ver­si­ty of Penn­syl­va­nia. It’s Hahn’s first move in­to the in­dus­try since re­sign­ing as FDA com­mis­sion­er on Jan. 20 at the con­clu­sion of Pres­i­dent Trump’s ad­min­is­tra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER